• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Taiwan Pharmaceutical Market Outlook 2013 - Product Image

Taiwan Pharmaceutical Market Outlook 2013

  • ID: 2564211
  • June 2013
  • Region: Taiwan
  • 128 Pages
  • GBI Research

FEATURED COMPANIES

  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Sanofi
  • ScinoPharm Taiwan
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research ""Taiwan Pharmaceutical Market Outlook 2013"". The report focuses on the Taiwanese pharmaceutical market, providing market analysis and a forecast to 2018. It provides details on the various market drivers and healthcare trends that influence growth in Taiwan’s pharmaceutical industry. The report also profiles major biopharmaceutical companies in the country, both domestic and overseas players.

Taiwan’s pharmaceutical market was worth $4.4 billion in 2012, having grown at a CAGR of 2.9%, and is estimated to reach $5.5 billion by 2018, growing at a CAGR of 3.9%. Although the size of the market is small compared with other growing markets in Asia, it is expected to provide a market entry point for companies wishing to launch their products in other larger markets.

Scope

- Political, economic and investment environment in Taiwan

- Healthcare and insurance system, healthcare infrastructure and key policy initiatives

- Market size estimation, analysis of key therapeutic areas and emerging areas

- Profiles of major biopharmaceutical companies in READ MORE >

FEATURED COMPANIES

  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Sanofi
  • ScinoPharm Taiwan
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Taiwan Pharmaceutical Market Outlook 2013 – Introduction
2.1 Taiwan Pharmaceutical Market

3 Taiwan Pharmaceutical Market Outlook 2013 – Investment Environment
3.1 Government and Political Environment
3.2 Taiwan Economic Outlook
3.3 Foreign Trade and Investment
3.4 Investment Incentives – Government Boosting the Biotech Sector
3.4.1 Act for the Development of Biotech and New Pharmaceuticals Industry (2007)
3.4.2 Diamond Action Plan for Biotechnology Takeoff (2009)
3.5 International Appraisal and Membership
3.5.1 Patent Prosecution Highway Pilot program
3.5.2 Pharmaceutical Inspection Convention and Inspection Cooperation Scheme

4 Taiwan Pharmaceutical Market Outlook 2013 – Healthcare System
4.1 Healthcare System
4.1.1 Department of Health
4.1.2 Bureau of National Health Insurance
4.1.3 Health Insurance Coverage
4.1.4 Health Insurance System Challenges
4.1.5 Health Policy Initiatives
4.2 Healthcare Expenditure
4.2.1 Healthcare Spending
4.2.2 Healthcare Expenditure by Type of Service
4.2.3 Healthcare Expenditure on Pharmaceutical Products
4.2.4 Public Health Expenditure
4.3 Healthcare Infrastructure
4.3.1 Healthcare Facilities
4.3.2 Healthcare Coverage
4.3.3 Healthcare Personnel
4.4 Population Health
4.4.1 Demographics
4.4.2 Life Expectancy
4.4.3 Mortality

5 Taiwan Pharmaceutical Market Outlook 2013 – Regulatory Landscape
5.1 Drug Pricing and Reimbursement
5.1.1 Drug Reimbursement
5.1.2 Pricing Policies
5.1.3 Pricing Trends
5.1.4 Challenges in the Reimbursement Process
5.1.5 Drug Expenditure Target
5.2 Policy and Regulatory Environment in Taiwan
5.2.1 New Drug Approval
5.2.2 Intellectual Property Rights

6 Taiwan Pharmaceutical Market Outlook 2013 – Market Overview
6.1 Pharmaceutical Market Overview
6.2 Pharmaceutical Market Size
6.3 Market Segments
6.4 Key Therapeutic Areas
6.4.1 Respiratory Diseases
6.4.2 Digestive Diseases
6.4.3 Genitourinary Diseases
6.4.4 Circulatory Diseases
6.4.5 Malignant Neoplasms
6.5 Emerging Areas
6.5.1 Orphan Drugs
6.6 Drug Distribution and Pharmaceutical Supply Chain
6.7 Spending in Pharmaceutical R&D

7 Taiwan Pharmaceutical Market Outlook 2013 – Competitive Landscape
7.1 Key Foreign Entities
7.1.1 Pfizer
7.1.2 Sanofi
7.1.3 Novartis
7.1.4 GlaxoSmithKline
7.2 Key Domestic Players
7.2.1 The China Chemical & Pharmaceutical Company
7.2.2 Standard Chemicals & Pharmaceuticals Co. Ltd.
7.2.3 Yung Shin Pharmaceutical. Ind. Co. Ltd.
7.2.4 ScinoPharm Taiwan
7.2.5 TTY Biopharm Company Limited

8 Taiwan Pharmaceutical Market Outlook 2013 – Market Dynamics
8.1 Industry Drivers and Opportunities
8.2 Barriers to Entry
8.3 Recent Industry Activity and Consolidation

9 Taiwan Pharmaceutical Market Outlook 2013 – the Way Forward
9.1 Key Insights
9.2 Market Opportunities
9.3 Future Market Outlook

10 Taiwan Pharmaceutical Market Outlook 2013 – Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables

Table 1: Pharmaceutical Market, Taiwan, Economic Indicators (%), 2008 – 2012 October
Table 2: Pharmaceutical Market, Taiwan, Trade with Top 10 Countries ($bn), 2012
Table 3: Pharmaceutical Market, Taiwan, Persons Under Social Insurance, (‘000, %), 2002 – 2012
Table 4: Pharmaceutical Market, Taiwan, BNHI Revenues and Costs ($bn), 2002 – 2012
Table 5: Pharmaceutical Market, Taiwan, National Health Expenditure (TWDbn, $bn), 2003 – 2012
Table 6: Pharmaceutical Market, Taiwan, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012
Table 7: Pharmaceutical Market, Taiwan, OECD Countries, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012
Table 8: Pharmaceutical Market, Taiwan, NHI Healthcare Expenditure by Type of Service ($bn), 2006 – 2011
Table 9: Pharmaceutical Market, Taiwan, Drug Expenditure ($bn), 2006 – 2012
Table 10: Pharmaceutical Market, Taiwan, Pharmaceutical Product Expenditure (%), 2006 – 2012
Table 11: Pharmaceutical Market, Taiwan, OECD Countries, Drug Expenditure (%), 2006 – 2012
Table 12: Pharmaceutical Market, Taiwan, OECD Countries, Out-of-Pocket Expenditure as Percentage of Healthcare Expenditure (%), 2006 – 2012
Table 13: Pharmaceutical Market, Taiwan, Public-Private Share of Healthcare Expenditure (%), 2006 – 2012
Table 14: Pharmaceutical Market, Taiwan, OECD Countries, Public Spending as Percentage of Total Health Expenditure (%), 2006 – 2012
Table 15: Pharmaceutical Market, Taiwan, NHI-contracted Healthcare Institutions by Type, 2006 – 2012
Table 16: Pharmaceutical Market, Taiwan, Hospital Beds per 1,000 Population, 2006 – 2012
Table 17: Pharmaceutical Market, Taiwan, OECD Countries, Hospital Beds per 1,000 Population, 2006 – 2012
Table 18: Pharmaceutical Market, Taiwan, Physicians per 1,000 Population, 2006 – 2012
Table 19: Pharmaceutical Market, Taiwan, OECD Countries, Physicians per 1,000 Population, 2006 – 2012
Table 20: Pharmaceutical Market, Taiwan, Nurses per 1,000 Population, 2006 – 2012
Table 21: Pharmaceutical Market, Taiwan, Healthcare Professionals by Type (‘000), 2006 – 2012
Table 22: Pharmaceutical Market, Taiwan, Pharmacists per 1,000 Population, 2006 – 2012
Table 23: Pharmaceutical Market, Taiwan, Population by Gender (‘000), 2006 – 2012
Table 24: Pharmaceutical Market, Taiwan, Population by Age (%), 2002 – 2012
Table 25: Pharmaceutical Market, Taiwan, Life Expectancy at Birth by Gender and Age (Years), 2002 – 2011
Table 26: Pharmaceutical Market, Taiwan, Life Expectancy at Birth (Years), 2004 – 2011
Table 27: Pharmaceutical Market, OECD Countries, Life Expectancy at Birth (Years), 2004 – 2011
Table 28: Pharmaceutical Market, Taiwan, Mortality Rate (per 1,000 population), 2002 – 2011
Table 29: Pharmaceutical Market, Taiwan, Cause of Deaths by Type of Disease (‘000), 2002 – 2011
Table 30: Pharmaceutical Market, Taiwan, Price Trend in Medicines and Medical Care (%), 2006 – 2012
Table 31: Pharmaceutical Market, Taiwan Intellectual Property Rights, 2012
Table 32: Pharmaceutical Market, Taiwan, Revenue ($bn, TWDbn), 2006 – 2012
Table 33: Pharmaceutical Market, Taiwan, Revenue Forecast ($bn, TWDbn), 2012 – 2018
Table 34: Pharmaceutical Market, Taiwan, Generics, Revenue ($bn), 2006 – 2012
Table 35: Pharmaceutical Market, Taiwan, Generics, Revenue Forecast ($bn), 2012 – 2018
Table 36: Pharmaceutical Market, Taiwan, Over-the-Counter, Revenue ($m), 2006 – 2012
Table 37: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area ($bn), 2006 – 2012
Table 38: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area and Age ($m), 2012
Table 39: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases ($m), 2006 – 2012
Table 40: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases by Year and Age ($m), 2006 – 2012
Table 41: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year ($m), 2006 – 2012
Table 42: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year and Age ($m), 2006 – 2012
Table 43: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases ($m), 2006 – 2012
Table 44: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases by Year and Age ($m), 2006 – 2012
Table 45: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year ($m), 2006 – 2012
Table 46: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year and Age ($m), 2006 – 2012
Table 47: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year ($m), 2006 – 2012
Table 48: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year and Age ($m), 2006 – 2012
Table 49: Pharmaceutical Market, Taiwan, Top Five Leading Causes of Cancer, Males, Incidence Rate, 2006 and 2008
Table 50: Pharmaceutical Market, Taiwan, Top Five Leading Causes of Cancer, Females, Incidence Rate, 2006 and 2008
Table 51: Pharmaceutical Market, Taiwan, Government Interventions for Cancer Prevention and Control, 1995 – 2008
Table 52: Pharmaceutical Market, Taiwan, Market Comparison between the US and Taiwan, 2012
Table 53: Pharmaceutical Market, Taiwan, R&D Expenditure ($m), 2005 – 2011
Table 54: Pharmaceutical Market, Global, Pfizer, Revenue ($bn), 2007 – 2012
Table 55: Pharmaceutical Market, Taiwan, Pfizer, Major Products by Type, 2012
Table 56: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Therapy Area, 2012
Table 57: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Development Phase, 2012
Table 58: Pharmaceutical Market, Global, Sanofi, Revenue ($bn), 2007 – 2012
Table 59: Pharmaceutical Market, Taiwan, Sanofi, Major Products by Therapy Area, 2012
Table 60: Pharmaceutical Market, Global, Sanofi, Number of Pipeline Products by Therapy Area, 2012
Table 61: Pharmaceutical Market, Global, Sanofi, Number of Pipeline Products by Development Phase, 2012
Table 62: Pharmaceutical Market, Global, Novartis, Financial Performance ($bn), 2007 – 2012
Table 63: Pharmaceutical Market, Global, Novartis, Major Products by Therapy Area, 2012
Table 64: Pharmaceutical Market, Global, Novartis, Number of Pipeline Products by Therapy Area, 2012
Table 65: Pharmaceutical Market, Global, Novartis, Number of Pipeline Products by Developmental Phase, 2012
Table 66: Pharmaceutical Market, Global, GlaxoSmithKline, Financial Performance ($m), 2007 – 2012
Table 67: Pharmaceutical Market, Global, GlaxoSmithKline, Major Products, Therapy Areas, Brands, 2012
Table 68: Pharmaceutical Market, Global, GlaxoSmithKline, Number of Pipeline Products by Therapy Area, 2012
Table 69: Pharmaceutical Market, Global, GlaxoSmithKline, Number of Pipeline Products by Development Phase, 2012
Table 70: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012
Table 71: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Major Products by Therapy Area, 2012
Table 72: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceutical, Revenue ($m) 2007 – 2012
Table 73: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Major Products, 2012
Table 74: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Product Patents, 2001 – 2010
Table 75: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Product Awards, 2001 – 2010
Table 76: Pharmaceutical Market, Taiwan, Yung shin Pharmaceutical, Revenue ($m), 2007 – 2012
Table 77: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceutical, Product Lines, 2012
Table 78: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceuticals, Latest Products by Disease Type, 2012
Table 79: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceuticals, Major Products, Active Pharmaceutical Ingredients, 2012
Table 80: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Revenue ($m), 2007 – 2012
Table 81: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Sales by Region (%), 2011
Table 82: Pharmaceutical Market, Taiwan, ScinoPharm, Major Products by Therapeutic Area, 2012
Table 83: Pharmaceutical Market, Taiwan, TTY Biopharm, Revenue ($m), 2007 – 2012
Table 84: Pharmaceutical Market, Taiwan, TTY Biopharm, Major Products by Therapy Area, 2012
Table 85: Pharmaceutical Market, Taiwan, TTY Biopharm, Pipeline Products by Therapy Area and Development Phase, 2012

1.2 List of Figures

Figure 1: Pharmaceutical Market, Taiwan, Economic Indicators (%), 2008 – 2012 October
Figure 2: Pharmaceutical Market, Taiwan, Trade with Top 10 Countries ($bn), 2012
Figure 3: Pharmaceutical Market, Taiwan, BNHI’s Function in Taiwan’s Healthcare System, 2012
Figure 4: Pharmaceutical Market, Taiwan, BNHI Revenues and Cost ($bn), 2002 – 2012
Figure 5: Pharmaceutical Market, Taiwan, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012
Figure 6: Pharmaceutical Market, Taiwan, OECD Countries, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012
Figure 7: Pharmaceutical Market, Taiwan, NHI Healthcare Expenditure of Type of Service (%), 2011
Figure 8: Pharmaceutical Market, Taiwan, Drug Expenditure ($bn), 2006 – 2012
Figure 9: Pharmaceutical Market, Taiwan, OECD Countries, Drug Expenditure (%), 2006 – 2012
Figure 10: Pharmaceutical Market, Taiwan, Out-of-Pocket Expenditure as Percentage of Healthcare Expenditure (%), 2006 – 2012
Figure 11: Pharmaceutical Market, Taiwan, NHI-contracted Healthcare Institutions by Type, 2006 – 2012
Figure 12: Pharmaceutical Market, Taiwan, OECD Countries, Hospital Beds per 1,000 Population, 2006 – 2012
Figure 13: Pharmaceutical Market, Taiwan, Physicians per 1,000 Population, 2006 – 2012
Figure 14: Pharmaceutical Market, Taiwan, OECD Countries, Physicians per 1,000 Population, 2006 – 2012
Figure 15: Pharmaceutical Market, Taiwan, Nurses per 1,000 Population, 2006 – 2012
Figure 16: Pharmaceutical Market, Taiwan, Pharmacists per 1,000 Population, 2006 – 2012
Figure 17: Pharmaceutical Market, Taiwan, Population by Gender, (‘000), 2006 – 2012
Figure 18: Pharmaceutical Market, Taiwan, Population by Age (%), 2002 – 2012
Figure 19: Pharmaceutical Market, Taiwan, Life Expectancy at Birth by Gender and Age (Years), 2002 – 2011
Figure 20: Pharmaceutical Market, Taiwan, OECD Countries, Life Expectancy at Birth (Years), 2004 – 2011
Figure 21: Pharmaceutical Market, Taiwan, Cause of Death by Type of Disease (‘000, %), 2002 – 2011
Figure 22: Pharmaceutical Market, Taiwan, Pricing and Reimbursement by Drug Type, 2012
Figure 23: Pharmaceutical Market, Taiwan, Price Trend in Medicines and Medical Care (%), 2006 – 2012
Figure 24: Pharmaceutical Market, Taiwan, Revenue Forecast ($bn), 2006 – 2018
Figure 25: Pharmaceutical Market, Taiwan, Generics, Revenues ($bn), 2006 – 2012
Figure 26: Pharmaceutical Market, Taiwan, Generics, Revenue Forecast ($bn), 2012 – 2018
Figure 27: Pharmaceutical Market, Taiwan, Over-the-Counter, Revenue ($m), 2006 – 2012
Figure 28: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area (%), 2012
Figure 29: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area ($bn), 2006 – 2012
Figure 30: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area and Age ($m), 2012
Figure 31: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases ($m), 2006 – 2012
Figure 32: Pharmaceutical Market, Taiwan, Drug Expenditure on Respiratory Diseases ($m), 2006 – 2012
Figure 33: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases by Year and Age ($m), 2006 – 2012
Figure 34: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases ($m), 2006 – 2012
Figure 35: Pharmaceutical Market, Taiwan, Drug Expenditure on Digestive Diseases ($m), 2006 – 2012
Figure 36: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year and Age ($m), 2006 – 2012
Figure 37: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases ($m), 2006 – 2012
Figure 38: Pharmaceutical Market, Taiwan, NHE on Genitourinary Diseases, by Year and Age ($m), 2006 – 2012
Figure 39: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases ($m), 2006 – 2012
Figure 40: Pharmaceutical Market, Taiwan, Drug Expenditure on Circulatory Diseases ($m), 2006 – 2012
Figure 41: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year and Age ($m), 2006 – 2012
Figure 42: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms ($m), 2006 – 2012
Figure 43: Pharmaceutical Market, Taiwan, Drug Expenditure on Malignant Neoplasms ($m), 2006 – 2012
Figure 44: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year and Age ($m), 2006 – 2012
Figure 45: Pharmaceutical Market, Taiwan, R&D Expenditure ($m), 2005 – 2011
Figure 46: Pharmaceutical Market, Global, Pfizer, Revenue ($bn), 2007 – 2012
Figure 47: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Therapy Area, 2012
Figure 48: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Development Phase, 2012
Figure 49: Pharmaceutical Market, Global, Sanofi, Revenue ($bn), 2007 – 2012
Figure 50: Pharmaceutical Market, Global, Novartis, Revenue ($bn), 2007 – 2012
Figure 51: Pharmaceutical Market, Global, GlaxoSmithKline, Revenue ($bn), 2007 – 2012
Figure 52: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012
Figure 53: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012
Figure 54: Pharmaceutical Market, Taiwan, Yung shin Pharmaceutical, Revenue ($m), 2007 – 2012
Figure 55: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Revenue ($m), 2007 – 2012
Figure 56: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Sales by Region (%), 2011
Figure 57: Pharmaceutical Market, Taiwan, TTY Biopharm, Revenue ($m), 2007 – 2012

FEATURED COMPANIES

  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Sanofi
  • ScinoPharm Taiwan
  • MORE

Taiwan’s Pharmaceutical Market Expected to Reach $5.5 Billion by 2018

Taiwan’s healthcare is driven by a single-payer global budget system run by the Bureau of National Health Insurance (BNHI). National health expenditure stood at TWD 910.2 billion ($30.9 billion) in 2011 and will grow at a rate of 2.2% to reach TWD 937.6 billion ($31.6 billion) in 2012. Taiwan’s pharmaceutical market was worth $4.4 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 2.9% from 2006, and is estimated to reach $5.5 billion by 2018 at a CAGR of 3.9%. Some of the key drivers of growth in the forecast period are:

- The provision of incentives for the biotech sector in the form of investment support, as part of the National Development Fund, worth TWD60 billion ($1.8 billion) in the coming six to 10 years. The Department of Health (DoH) and BNHI have introduced second-generation National Health Insurance (NHI), which is expected to improve pricing and regulatory policies. Research alliances with academic institutions and public-private partnerships are expected to boost research in new drug development, with several projects already underway and products already in late-stage clinical trials.

- The improving cross-straits relations with the People’s Republic of China (PRC) are expected to drive the market demand for drugs in common diseases. Trade relations improved with the recent signing of the Economic Cooperation Framework Agreement, and the Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs was signed especially to promote cooperation in medicine development and disease prevention. Taiwan could prove to be the launch pad for new drugs to gain access into the much larger Chinese market.

- An aging population, the rising prevalence of lifestyle disease and the increasing demand for new technologies in medicine are expected to drive market growth. The demand for new drugs in oncology and liver cancer is expected to increase, and circulatory and genitourinary diseases are other key therapeutic areas with growth potential.

- GlaxoSmithKline
- Novartis
- Pfizer
- Sanofi
- ScinoPharm Taiwan
- Standard Chemicals & Pharmaceuticals Co. Ltd.
- The China Chemical & Pharmaceutical Company
- TTY Biopharm Company Limited
- Yung Shin Pharmaceutical. Ind. Co. Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos